Decreased professional performance and quality of life in patients withmoderate-to-severe atopic eczema - Results from the German atopic eczema registry TREATgermany

被引:1
作者
Haufe, E. [1 ]
Abraham, S. [2 ]
Heratizadeh, A. [3 ]
Harder, I. [4 ]
Zink, A. [5 ]
Weisshaar, E. [6 ]
Kleinheinz, A. [7 ]
von Kiedrowski, R. [8 ]
Worm, M. [9 ]
Bell, M. [10 ]
Wollenberg, A. [11 ]
Neubert, K.
Staubach-Renz, P. [12 ]
Hilgers, M. [13 ]
Bieber, T. [14 ]
Fell, I. [15 ]
Homey, B. [16 ]
Effendy, I. [17 ]
Mempel, M.
Schaekel, K. [18 ]
Beissert, S. [2 ]
Weidinger, S. [4 ]
Werfel, T. [3 ]
Schmitt, J. [1 ]
机构
[1] Tech Univ Dresden, Univ Klinikum, Zentrum Evidenzbasierte Gesundheitsversorgung, Fetscherstr 74, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Univ Klinikum, Dermatol Klin & Poliklin, Dresden, Germany
[3] Hannover Med Sch, Klin Dermatol Allergol & Venerol, Hannover, Germany
[4] Univ Klinikum Schleswig Holstein, Klin Dermatol Venerol & Allergol, Campus Kiel, Kiel, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Dermatol & Allergol Biederstein, Munich, Germany
[6] Univ Klinikum Heidelberg, Abt Klin Sozialmed, Heidelberg, Germany
[7] Elbe Klinikum Buxtehude, Dermatol Klin, Buxtehude, Germany
[8] CMSS Co Study & Serv Selters Westerwald, Selters, Germany
[9] Charite, Klin Dermatol Venerol & Allergol, Berlin, Germany
[10] Dr Magnus Bell & Thomas Kaiser, Allergol, Andernach, Germany
[11] LMU Munchen, Klin & Poliklin Dermatol & Allergol, Munich, Germany
[12] Univ Med Mainz, Klin Dermatol & Allergol, Mainz, Germany
[13] Univ Klinikum Aachen, Klin Dermatol & Allergol, Aachen, Germany
[14] Univ Klinikum Bonn, Klin & Poliklin Dermatol & Allergol, Bonn, Germany
[15] Hautmed Bad Soden, Bad Soden, Germany
[16] Univ Klinikum Dusseldorf, Hautklin, Dusseldorf, Germany
[17] Klinikum Bielefeld Gem GmbH, Hautklin, Bielefeld, Germany
[18] Univ Hautklin Heidelberg, Heidelberg, Germany
关键词
atopic dermatitis; registry; costs; health economy; utilities; INDEX DLQI; EUROPEAN GUIDELINES; WORK LIMITATIONS; OUTCOME MEASURES; DERMATITIS; CONSENSUS; CHILDREN; ADULTS; CYCLOSPORINE; TRIALS;
D O I
10.5414/ALX02072
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Clinical registries may provide high quality evidence on the use and effectiveness of therapeutic interventions under real-life conditions. Adults with moderate-to-severe AD are enrolled into TREATgermany and prospectively followed over at least 2 years. The paper analyses the association between dermatological quality of life and work limitations. Materials and methods: Treatment modalities and a broad set of physician and patient reported outcome measures are documented using validated instruments to assess clinical disease severity (EASI, objective SCORAD), quality of life (DLQI), symptoms (POEM), global disease severity, as well as patient satisfaction and work limitations including presentism (WLQ). From 06/2016 until 12/2017, 241 individuals (mean age 43 +/- 15 years, 38.6% female) were enrolled at 19 recruitment centers. 69% of them were currently employed. Results: Employed persons had DLQI and WLQ scores of 10.4 +/- 6.9 points and 17.7 +/- 18.1%, respectively. Mean presentism was substantial accounting for 9.2%. With coefficients of 0.39 and 0.33 WLQ and presentism scores significantly correlate with DLQI (p < 0.000). Bootstrapped regression models showed that the limitations in coping with work requirements increase by 1.7% as DLQI increases by one point. Lower quality of life due to AD is most strongly associated with limitations in the area of physical and performance requirements in general. Presentism decreases by 0.5% as DLQI increases by one point. Conclusion: Moderate-to-severe AD has substantial adverse economic impact with mean productivity loss of patients of almost 10%. Future analyses from TREATgermany will address the impact of innovative treatment modalities on quality of life and work productivity of patients with moderate-to-severe AD.
引用
收藏
页码:266 / 274
页数:9
相关论文
共 34 条
[31]   Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study [J].
Rosmarin, David ;
Fretzin, Scott ;
Strowd, Lindsay ;
Casillas, Marta ;
DeLozier, Amy M. ;
Dawson, Zach ;
Chen, Sherry ;
Lu, Na ;
Thyssen, Jacob P. .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2022, 26 (04) :377-385
[32]   Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies [J].
Prajapati, Vimal H. ;
Bunick, Christopher G. ;
Eyerich, Kilian ;
Gold, Linda Stein ;
Galimberti, Fabrizio ;
Calimlim, Brian ;
Teixeira, Henrique ;
Hu, Xiaofei ;
Yang, Yang ;
Sancho, Cristina ;
Grada, Ayman ;
Irvine, Alan D. .
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[33]   Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7 [J].
Koji Masuda ;
Amy M. Delozier ;
Jill Kolodsick ;
Andrew Buchanan ;
Andrew E. Pink ;
Luna Sun ;
Zhongkai Wang ;
Luca Stingeni ;
Diamant Thaçi .
European Journal of Dermatology, 2022, 32 :237-243
[34]   Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7 [J].
Masuda, Koji ;
Delozier, Amy M. ;
Kolodsick, Jill ;
Buchanan, Andrew ;
Pink, Andrew E. ;
Sun, Luna ;
Wang, Zhongkai ;
Stingeni, Luca ;
Thaci, Diamant .
EUROPEAN JOURNAL OF DERMATOLOGY, 2022, 32 (02) :237-243